Root Financial Partners’s Galectin Therapeutics GALT Stock Holding History

Root Financial Partners’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$31	Buy	+8	New	+$31	﹤0.01%	3765

Other funds holding GALT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Geneos Wealth Management Englewood, Colorado $5.32B AUM 16.49% 1-Year Est. Return

Sovran Advisors San Diego, California $1.45B AUM 13.87% 1-Year Est. Return

Retirement Guys Formula Maumee, Ohio $269M AUM 17.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Root Financial Partners's GALT Position: Q3 2026 in Review

Root Financial Partners opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 8 shares worth $31. The stake represents ﹤0.01% of the portfolio and ranks #3765 among its holdings.

51 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

Root Financial Partners held 8 shares of Galectin Therapeutics worth $31 as of Q3 2026.
Galectin Therapeutics was a new Root Financial Partners position in Q3 2026.
Galectin Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3765 holding.
51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.